Eli Lilly just struck a major deal with the world's largest retailer. GLP-1 drugs may have uses beyond obesity and diabetes ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock are in focus as the companies are nearing to strike U.S. pricing deals for ...

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports ...

The boss of the Wegovy firm linked its reduced guidance to the market for weight-loss treatments being ‘more competitive than ...

A deal with Lilly and Novo would be significant for the administration’s push for lower drug prices for Americans.

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

The bank's lead analyst recognizes the importance of getting in early with potentially game-changing drug development.

Since tanking in early August, shares of Eli Lilly and Company (NYSE: LLY) have roared back with a vengeance. The world’s ...

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

Obesity drugs have become an increasingly popular method of weight loss but most are not covered by insurance for that ...

In today’s Pharmaceutical Executive Daily, we cover Pfizer’s lawsuits against Metsera and Novo Nordisk over alleged ...